Search hospitals > Colorado > Denver
Porter Adventist Hospital
Claim this profileDenver, Colorado 80210
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
388 reported clinical trials
5 medical researchers
Summary
Porter Adventist Hospital is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Porter Adventist Hospital is involved with conducting 388 clinical trials across 502 conditions. There are 5 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Douglas Dennis, MD, and Mehmet S. Copur.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
172 reported clinical trials
239 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Douglas Dennis, MDColorado Joint Replacement2 years of reported clinical research
Studies Osteoarthritis
Studies Water on the knee
6 reported clinical trials
9 drugs studied
Mehmet S. CopurBethesda North Hospital12 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
2 reported clinical trials
8 drugs studied
Clinical Trials running at Porter Adventist Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Cancer
Squamous Cell Carcinoma
Prostate Cancer
Bladder Carcinoma
Gastric Cancer
Pancreatic Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Porter Adventist Hospital?
Porter Adventist Hospital is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Porter Adventist Hospital is involved with conducting 388 clinical trials across 502 conditions. There are 5 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Douglas Dennis, MD, and Mehmet S. Copur.
Where is Porter Adventist Hospital located?
Porter Adventist Hospital is located at 2525 S Downing St, Denver, CO 80210.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Porter Adventist Hospital, contact the Patient Financial Services department at (802) 847-8000 or 800-639-2719, available Monday-Friday, 8:30 a.m. – 4 p.m. They provide financial assistance programs, eligibility assessment for government funding, and financial hardship treatment options. The hospital accepts various insurance plans, including Aetna, Blue Cross Blue Shield of Vermont, Cigna, Medicaid, Medicare, MVP, and United HealthCare; however, verify your plan's coverage directly with the hospital.
What insurance does Porter Adventist Hospital accept?
Porter Adventist Hospital, a member of Centura Health, accepts Cigna insurance plans. The hospital also accepts Medicare, Medicaid, various commercial managed care plans, exchange plans, and worker's compensation plans. It is recommended to contact the hospital directly to confirm the current accepted insurance plans.
What awards or recognition has Porter Adventist Hospital received?
Porter Adventist Hospital, located in Denver, Colorado, has earned Magnetâ„¢ Recognition from the American Nurses Credentialing Center, highlighting its excellence in nursing services. It is also recognized as one of America's highest-rated hospitals for patient safety by The Leapfrog Group.